Novo Nordisk Shares Under Pressure as US Pricing Deal and Acquisition Battle Intensify
Published on 11/10/2025 at 03:41 | Redaktion boerse-global.de
Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent waters following a significant pricing agreement with US authorities and an escalating bidding war for a key biotechnology firm. The developments have sparked concerns among investors about the company’s ability to balance revenue pressures with strategic expansion needs.
In a move that will substantially reduce patient expenses, Novo Nordisk and competitor Eli Lilly have reached a settlement with the US government regarding pricing for GLP-1 medications, including the weight-loss treatment Wegovy. The arrangement, confirmed on Thursday, November 6, will lower monthly costs for Medicare, Medicaid, and self-paying patients to a range of $149 to $350. Previously, these medications carried price tags between $500 and Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
